%0 Generic
%A Cottu, P. H.
%A Ring, A.
%A Marchetti, P.
%A Cardoso, F.
%A Salvador, J.
%A Neven, P.
%A Papazisis, K.
%A Campone, M.
%A Bachelot, T.
%A Menon-Singh, L.
%A Wu, J.
%A Zhou, K.
%A De laurentiis, M.
%T Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
%D 2020
%@ 0923-7534
%U https://hdl.handle.net/10668/27218
%~